Jun 10, 2020 / 12:00PM GMT
Graig Suvannavejh - Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst
Great. Well good morning, everyone. Thanks to everyone for joining us this morning. My name is Graig Suvannavejh, and I am a U.S. and European biopharma analyst at Goldman Sachs. With me today are Tim Hauwermeiren -- Van Hauwermeiren. Sorry if I butchered your name, Tim. Everyone butchers my name, so my apologies for that -- CEO of the company; and Keith Woods, who is Chief Operating Officer of the company. And so today, we're going to have a discussion on argenx. And with that said, obviously, we want to lead maybe straight off with talking with Tim, just about the successes that argenx has had. Tim cofounded the company back in 2008. We're now in 2020.
Questions and Answers:
Graig Suvannavejh - Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research AnalystSo maybe if we could just start with maybe a high-level brief perspective of kind of the vision you saw for argenx 12 years ago. And maybe
Trustpilot
